SG Americas Securities’s Audentes Therapeutics, Inc BOLD Stock Holding History

SG Americas Securities’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-326,905	Closed	-$19.6M	–	3810
2019 Q4	$19.6M	Buy	326,905 +297,494	+1,012%	+$11.2M	0.18%	91
2019 Q3	$826K	Sell	29,411 -80,509	-73%	-$2.75M	0.01%	1528
2019 Q2	$4.16M	Buy	109,920 +102,618	+1,405%	+$3.94M	0.03%	629
2019 Q1	$285K	Buy	+7,302	New	+$209K	﹤0.01%	2309
2017 Q4	–	Sell	-5,094	Closed	-$143K	–	3838
2017 Q3	$143K	Buy	+5,094	New	+$111K	﹤0.01%	2899
2017 Q1	–	Sell	-7,569	Closed	-$138K	–	3684
2016 Q4	$138K	Buy	+7,569	New	+$131K	﹤0.01%	2638

SG Americas Securities's BOLD Position: Q1 2020 in Review

SG Americas Securities sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 326,905 shares — an estimated $19.6M sold.

SG Americas Securities first reported a position in BOLD in Q4 2016 and held it in 6 quarters. The position peaked at $19.6M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

SG Americas Securities reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
SG Americas Securities sold 326,905 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $19.6M.
SG Americas Securities first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 6 quarters.
SG Americas Securities's Audentes Therapeutics, Inc position peaked at $19.6M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on SG Americas Securities's 13F filing for Q1 2020, filed 30 Apr 2020.